• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Thymectomy effective in patients with non-thymomatous myasthenia gravis: The MGTX trial

byJames RoebkerandShaidah Deghan, MSc. MD
August 12, 2016
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Thymectomy with prednisone was significantly more effective than prednisone alone in reducing disease severity and prednisone requirements in non-thymomatous myasthenia gravis (MG).

2. While treatment-associated complications between thymectomy with prednisone and prednisone alone were similar, thymectomy also improved other clinical outcomes regarding safety and quality of life.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Thymic abnormalities – hyperplasia or thymomas – are found in the majority of patients with MG. Given the clear association, thymectomy has been used to treat patients regardless of the type of pathologic change. Yet, no randomized trials have examined the benefit in MG patients without a thymoma. This study assessed the safety and efficacy of thymectomy versus prednisone alone in this cohort. Primary outcomes of interest measured efficacy based on the Quantitative Myasthenia Gravis score (QMGS) and prednisone requirements over a 3-year period and demonstrated significant benefit in the thymectomy group. Secondary outcomes included various measures of safety and quality of life and further supported the beneficial role of thymectomy in non-thymomatous patients with MG.

At the 3-year end point, the time-weighted QMGS and the time-weighted estimated prednisone dose was significantly lower in the thymectomy group compared to prednisone only group. Furthermore, there were significantly fewer treatment associated symptoms, hospitalizations, azathioprine use, and lower number of patients reaching minimal manifestation status in the thymectomy group compared to the prednisone group. Weaknesses include the lack of scientific rigor in the pill count method used to measure prednisone requirements and the risk of experimenter bias due to only single-blinding.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis

Relevant Reading: Is thymectomy in non-thymomatous myasthenia gravis of any benefit?

In-Depth [randomized controlled trial]: The MGTX trial was a multicenter, randomized, controlled trial that included a total of 7513 participants. All patients were administered prednisone if not already receiving it at baseline. Half were randomized to the thymectomy group while the other half only received prednisone. The primary outcomes were the time-weighted QMGS and time-weighted prednisone requirements at 3 years. Secondary outcomes included adverse events (hospitalization days over the 3-year period), clinically validated QOL surveys and a quantitative daily living score, patients who achieved minimal-manifestation status, and the use of other nonglucocorticoid treatments.

Through the first 3 years of the trial, the time-weighted QMGS was an estimated 2.85 points lower (99.5%CI 0.47 to 5.22; p < 0.001) and the time-weighted average prednisone dose was an estimated 16 mg lower (95%CI 7 to 25; p < 0.001) in the thymectomy versus prednisone-alone group. No significant difference was found between treatment associated complications based on patient surveys (p = 0.73), though surveys indicated fewer treatment associated symptoms in the thymectomy group (p < 0.001). Significantly fewer patients were hospitalized in the thymectomy group (9% vs. 37%, p < 0.001). The thymectomy group demonstrated a significantly lower level of azathioprine use (17% vs. 48%, p < 0.001), lower percentage of patients reaching minimal-manifestation status at the 3-year period (67% vs 47%, p = 0.03), and scores on the MG Activities of Daily Living scale (2.24 vs. 3.41, p = 0.008).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Myasthenia Gravis
Previous Post

Frozen-embryo transfer associated with higher live birth in women with PCOS

Next Post

Reporting of maltreatment for prenatal exposure similar among racial groups

RelatedReports

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis
StudyGraphics

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

April 23, 2025
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Chronic Disease

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

September 28, 2022
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Neurology

Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis

April 6, 2016
Health A to Z

Patient Basics: Myasthenia Gravis

November 30, 2014
Next Post
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Reporting of maltreatment for prenatal exposure similar among racial groups

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

Late gestation antidepressant use linked to postpartum hemorrhage

Forceps simulation associated with reduction in severe perineal lacerations

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.